IVA logo

IVA Inventiva S.A.

NASDAQ Global Market · Biotechnology · Healthcare

$3.14
-0.31 (-8.99%)

Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH…

Market Cap: $163.22Mwww.inventivapharma.com

Price

No data yet.

Social Signal Score

56
5d
—
30d
—
60d
55
6 mentions
—
90d
57
7 mentions
—
news: 7

Analyst Ratings

9 analysts
Buyconsensus
Strong Buy 0Buy 8Hold 0Sell 1Strong Sell 0
Avg price target$14+345.9%
Low $14Median $14High $14
Current Consensus

Revenue

$1.30M+70.34%
$28.8K$5.53M$11.04M$16.54M
Jan 2013Jun 2026

Analyst Estimates

FY2025
$-1.40
$-2.10–$-0.75
5 analysts
FY2026
$-0.61
$-0.79–$-0.48
5 analysts
FY2027
$-0.60
$-0.86–$-0.40
5 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Andrew Obenshain
Sector
Healthcare
Industry
Biotechnology
Employees
77
Beta
0.91
Country
FR
Piotroski score
3 / 9 (Weak)
Altman Z-score
-0.65
www.inventivapharma.com